Entdecken Sie jetzt unsere neuen Themengebiete
Pharma &
Biotech
 Champignon Brands /  12. Juni 2020 /  1474 Aufrufe

Presented by CSE and CFN Media

Presented as part of CSE and CFN Media's exclusive video series on Investing in Psychedelics. This interview with Champignon Brands (CSE SHRM / WKN A2PZ48) CEO Dr. Roger McIntyre highlights his company's focus on the formulation and manufacturing of novel ketamine, anaesthetics, and adaptogenic delivery platforms for nutraceutical and psychedelic medicine while being supported by a leading psychedelics medicines clinic platform. The Company is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders.

Under a collaborative research agreement with the University of Miami's Miller School of Medicine, the Company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability as its medicinal mushroom-infused SKUs are organic, non-GMO, and vegan certified.

Subscribe to CSE TV to learn more about up-and-coming companies in the private and public sectors that are paving the way for the psychedelics industry with their innovative applications. Future videos in this series will also feature experts in the brokerage and banking world discussing where to find investment opportunities and what due diligence looks like when it comes to the psychedelics market.

Kommentar schreiben

Ähnliche Videos

Wir setzen Cookies zum Betrieb und zur Sicherheit der Seite ein, aber auch Dienste Dritter setzen Cookies zum Webtracking bzw. Marketing.
Hinweise zum Datenschutz, Dienste Dritter und Widerspruch finden Sie in unserer Datenschutzerklärung